We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
14 November 2018
On 20 August 2018, the Federal Court dismissed Valeant's application under the Patented Medicines (Notice of Compliance) regulations regarding Ranbaxy's bupropion extended-release tablets (Valeant's Wellbutrin XL) and Patent 2,524,300. Justice McVeigh held that Ranbaxy's allegation of non-infringement was justified (Valeant Canada LP v Ranbaxy Pharmaceuticals Canada Inc, 2018 FC 847). McVeigh:
Therefore, the amount of permeation enhancer in the Ranbaxy formulation was outside the scope of the range claimed and Ranbaxy's allegation of non-infringement was found to be justified.
For further information on this topic please contact Tierney GB Deluzio at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (firstname.lastname@example.org). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.